^
    1d
    Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management (clinicaltrials.gov)
    P1, N=0, Withdrawn, Virginia Commonwealth University | N=10 --> 0 | Trial completion date: Jan 2027 --> Jun 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Jun 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    5-fluorouracil
    1d
    Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    2d
    Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery (clinicaltrials.gov)
    P3, N=288, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P3 trial
    |
    capecitabine
    2d
    NFYA Activates REG1A Expression to Promote Malignant Progression and Chemosensitivity in Rectal Cancer. (PubMed, Ann Clin Lab Sci)
    NFYA promoted REG1A expression, and the NFYA-REG1A axis enhanced RC resistance to RT and CT and malignant progression.
    Journal
    |
    REG1A (Lithostathine-1-alpha)
    |
    5-fluorouracil
    2d
    Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis. (PubMed, Ther Adv Med Oncol)
    Patients underwent 135 sessions using either HepaSphere beads plus HAIC-FOLFOX (HEPA-HAIC, n = 33) or DC bead plus HAIC-FOLFOX (DCB-HAIC, n = 29)...Nausea, vomiting, and severe pain were significantly less frequent with HEPA-HAIC (5.6% vs 31.7%, p = 0.001; 4.2% vs 31.7%, p < 0.001; 8.3% vs 22.2%, p = 0.01). DEB-TACE plus HAIC was feasible and demonstrated intrahepatic disease control with acceptable tolerability in unresectable GCLM; HEPA-HAIC showed a favorable safety profile.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    5-fluorouracil • leucovorin calcium • DC Bead (E7040)
    2d
    Targeting ATF4 overcomes dual resistance to chemo-immunotherapy in gastric cancer by disrupting the DNA damage response. (PubMed, J Immunother Cancer)
    These findings establish the ATF4-HSPA9 axis as a dual-function therapeutic target and predictive biomarker in GC chemo-immunotherapy. This axis bridges DNA damage repair-mediated chemoresistance and T cell exhaustion, providing a strategy to overcome resistance to 5-FU and PD-1 blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ATF4 (Activating Transcription Factor 4) • HSPA9 (Heat Shock Protein Family A (Hsp70) Member ) • TCF4 (Transcription Factor 4)
    |
    5-fluorouracil
    2d
    Prostate brachytherapy followed by secondary urethral adenocarcinoma: A case report. (PubMed, Urol Case Rep)
    After neoadjuvant oxaliplatin/capecitabine (CAPOX) therapy, he underwent cystoprostatectomy, urethrectomy, and ileal conduit. Pathology showed stage IIIB disease with negative margins. This case underscores a rare but severe complication of prostate brachytherapy, contributing to the clinical understanding of secondary urethral malignancies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • oxaliplatin
    5d
    Damage-associated molecular pattern scoring system and its role in prognosis and immunotherapy in hepatocellular carcinoma. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban)
    The prognostic risk scoring model constructed based on DAMP-related genes can effectively stratify HCC patients and is closely associated with characteristics of the tumor immune microenvironment. The DAMP scoring model established in this study may be used for prognostic evaluation and prediction of immunotherapy efficacy in HCC and demonstrated stable predictive performance across multiple cohorts. As a hub gene in this DAMP scoring model, TRIP13 exerts oncogenic effects in HCC and regulates tumor cell sensitivity to the ICD inducer 5-FU. The DAMP-score-based subtype classification system and TRIP13-targeted therapy provide new molecular evidence for individualized treatment of HCC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TRIP13 (Thyroid Hormone Receptor Interactor 13)
    |
    5-fluorouracil
    5d
    Management of locally advanced lynch syndrome rectal cancer during pregnancy with neoadjuvant immunochemotherapy: a case report. (PubMed, Front Oncol)
    The patient subsequently underwent neoadjuvant chemoradiotherapy (50.4 Gy in 28 fractions) combined with two cycles of capecitabine plus oxaliplatin (CapeOx) and tislelizumab, achieving significant tumor regression (yT2N0M0). LS-associated rectal cancer during pregnancy requires individualized, multidisciplinary management. Medical termination followed by neoadjuvant immunochemoradiotherapy can optimize maternal outcomes while minimizing fetal and genetic risks.
    Journal
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    6d
    A Clinical Study of Arfolitixorin in Patients With mCRC (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Isofol Medical AB | Trial completion date: Mar 2029 --> Dec 2029 | Trial primary completion date: Mar 2028 --> Nov 2028 | N=60 --> 90
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    RAS mutation
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • Modufolin (arfolitixorin)
    6d
    CapTemY90 for Grade 2/3 NET Liver Metastases (clinicaltrials.gov)
    P2, N=70, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: May 2026 --> Jul 2028 | Trial primary completion date: May 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    temozolomide • capecitabine
    6d
    SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)